Work presented here outlines one avenue of SEMA3C regulation and is intended to inspire future work which will be needed to fully understand the mechanisms governing elevated SEMA3C levels in prostate cancer patients containing FOXA1 alterations. Here, FOXA1 is linked to prostate carcinoma.